Marchese, Shelby http://orcid.org/0000-0003-0364-9676
Cancelmo, Leo
Diab, Olivia
Cahn, Leah
Aaronson, Cindy
Daskalakis, Nikolaos P. http://orcid.org/0000-0003-1660-9112
Schaffer, Jamie
Horn, Sarah R.
Johnson, Jessica S.
Schechter, Clyde
Desarnaud, Frank
Bierer, Linda M.
Makotkine, Iouri
Flory, Janine D.
Crane, Michael
Moline, Jacqueline M.
Udasin, Iris G.
Harrison, Denise J.
Roussos, Panos http://orcid.org/0000-0002-4640-6239
Charney, Dennis S.
Koenen, Karestan C.
Southwick, Steven M.
Yehuda, Rachel
Pietrzak, Robert H.
Huckins, Laura M. http://orcid.org/0000-0002-5369-6502
Feder, Adriana http://orcid.org/0000-0003-2931-310X
Article History
Received: 11 July 2021
Revised: 16 November 2021
Accepted: 18 January 2022
First Online: 17 February 2022
Competing interests
: AF and DSC are named co-inventors on a patent application in the US, and several issued patents outside the US, filed by the Icahn School of Medicine at Mount Sinai (ISMMS) related to the use of ketamine for the treatment of PTSD. This intellectual property has not been licensed. DSC is named co-inventor on patents filed by the ISMMS relating to the treatment for treatment-resistant depression, suicidal ideation and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), DSC is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, DSC will be entitled to additional payments, beyond those already received, under the license agreement. DSC is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, DSC has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. DSC is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered Neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. The other authors declare no conflicts of interest.